Gapping up
In reaction to strong earnings/guidance: HZNP +7.9%, EXAS +3.2%, HAL +3.2%, MS +3.1%, LMT +1.4%, HAS +1%
M&A news: VSLR +42.9% (SunEdison (SUNE) to acquire Vivint Solar for ~$2.2 bln; under the merger agreement, Vivint Solar stockholders will receive $16.50/share), UTX +1.1% (Lockheed Martin confirms it will acquire Sikorsky Aircraft from UTX for $9.0 billion)
Other news: EXEL +33% (announces positive top-line results from METEOR, the Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma), DCTH +23% (confirms receipt of Orphan Drug Designation From FDA For Melphalan to treat Cholangiocarcinoma), HCLP +10.3% (Barron's profiles positive view on the MLP space), AMRS +8.8% (cont strength), FRO +7.5% (likely due to clearer outlook for Greece), VLTC +4.4% (cont strength), DRYS +3.7% (likely due to clearer outlook for Greece), NBG +3.5% (Greek banks open up today), GPRO +3.3% (cont strength), GRFS +2.7% (announces a $700 mln contract through 2026 with Abbott (ABT) for the production of antigens), NVO +1.3% (still checking), MT +1.2% (positive Barrons article), CLF +1% (may be in tandem with MT), YHOO +0.8% (announces the initial filing with the SEC for the planned spin-off of its Alibaba (BABA) stake)
Analyst comments: CLVS +4.1% (added to Conviction Buy List at Goldman), GRNT +3.8% (initiated with a Buy at UBS), EMES +3.1% (upgraded to Neutral at Robert W. Baird), CLLS +3.1% (initiated with a Buy at BofA/Merrill), AMZN +1.7% (upgraded to Outperform at Cowen), STNG +1.6% (upgraded to Overweight from Neutral at JP Morgan), UPL +1.6% (upgraded to Buy from Accumulate at KLR Group), TXN +1.1% (upgraded to Buy from Neutral at UBS), SLB +1% (upgraded to Outperform from Market Perform at Wells Fargo)
In reaction to strong earnings/guidance: HZNP +7.9%, EXAS +3.2%, HAL +3.2%, MS +3.1%, LMT +1.4%, HAS +1%
M&A news: VSLR +42.9% (SunEdison (SUNE) to acquire Vivint Solar for ~$2.2 bln; under the merger agreement, Vivint Solar stockholders will receive $16.50/share), UTX +1.1% (Lockheed Martin confirms it will acquire Sikorsky Aircraft from UTX for $9.0 billion)
Other news: EXEL +33% (announces positive top-line results from METEOR, the Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma), DCTH +23% (confirms receipt of Orphan Drug Designation From FDA For Melphalan to treat Cholangiocarcinoma), HCLP +10.3% (Barron's profiles positive view on the MLP space), AMRS +8.8% (cont strength), FRO +7.5% (likely due to clearer outlook for Greece), VLTC +4.4% (cont strength), DRYS +3.7% (likely due to clearer outlook for Greece), NBG +3.5% (Greek banks open up today), GPRO +3.3% (cont strength), GRFS +2.7% (announces a $700 mln contract through 2026 with Abbott (ABT) for the production of antigens), NVO +1.3% (still checking), MT +1.2% (positive Barrons article), CLF +1% (may be in tandem with MT), YHOO +0.8% (announces the initial filing with the SEC for the planned spin-off of its Alibaba (BABA) stake)
Analyst comments: CLVS +4.1% (added to Conviction Buy List at Goldman), GRNT +3.8% (initiated with a Buy at UBS), EMES +3.1% (upgraded to Neutral at Robert W. Baird), CLLS +3.1% (initiated with a Buy at BofA/Merrill), AMZN +1.7% (upgraded to Outperform at Cowen), STNG +1.6% (upgraded to Overweight from Neutral at JP Morgan), UPL +1.6% (upgraded to Buy from Accumulate at KLR Group), TXN +1.1% (upgraded to Buy from Neutral at UBS), SLB +1% (upgraded to Outperform from Market Perform at Wells Fargo)